来源:药渡撰文:Pharmadeep编辑:维他命近日,国内IL-4Rα抗体赛道迎来新进展。2月25日至26日,国家药品监督管理局药品审评中心官网先后公示,康方生物自主研发的曼多奇单抗与三生国健自主研发的SSGJ-611两款重组抗IL-4Rα人源化单抗注射液的新药上市申请相继获得受理,适应症均聚焦于中重度特应性皮炎。这标志着继康诺亚司普奇拜单抗率先打破进口垄断后,国产IL-4Rα单抗正密集进入申报...
Source Link来源:药渡撰文:Pharmadeep编辑:维他命近日,国内IL-4Rα抗体赛道迎来新进展。2月25日至26日,国家药品监督管理局药品审评中心官网先后公示,康方生物自主研发的曼多奇单抗与三生国健自主研发的SSGJ-611两款重组抗IL-4Rα人源化单抗注射液的新药上市申请相继获得受理,适应症均聚焦于中重度特应性皮炎。这标志着继康诺亚司普奇拜单抗率先打破进口垄断后,国产IL-4Rα单抗正密集进入申报...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.